New drug PM54 enters human testing for Hard-to-Treat cancers

NCT ID NCT05841563

Recruiting now Disease control Sponsor: PharmaMar Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated May 21, 2026 · Updated 33 times

Summary

This early-phase study tests a new drug called PM54 in about 125 adults with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose by watching for side effects; the second part checks if the drug can shrink tumors. The goal is to control the disease, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

HM Universitario Sanchinarro
RECRUITING

Madrid, M, 28050, Spain

Contact
Institut Jules Bordet
RECRUITING

Anderlecht, 1070, Belgium

Contact
South Texas Accelerated Research Therapeutics
RECRUITING

San Antonio, Texas, 78229-3307, United States

Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR